Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.51 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.

Earnings